Skip Navigation

Schizophrenia Bulletin 2003 29(1):95-104;
© 2003 by Oxford University Press and the Maryland Psychiatric Research Center (MPRC)
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Domino, M. E.
Right arrow Articles by Rosenheck, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Domino, M. E.
Right arrow Articles by Rosenheck, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press

The Diffusion of New Antipsychotic Medications and Formulary Policy

Marisa Elena Domino, Ph.D., Richard G. Frank, Ph.D. and Robert Rosenheck, M.D.
Assistant Professor, Department of Health Policy and Administration, University of North Carolina School of Public Health Chapel Hill, NC
Margaret T. Morris Professor of Health Economics, Department of Health Care Policy, Harvard Medical School Cambridge, MA
Director, Northeast Program Evaluation Center, VA Connecticut Health Care System West Haven, CT; and Professor of Psychiatry and Public Health, Yale Medical School New Haven, CT

Send reprint requests to Dr. M. Domino, Assistant Professor of Health Economics, Department of Health Policy and Administration, UNC at Chapel Hill, 1104G McGavran-Greenberg Hall, CB# 7411, Chapel Hill, NC 27599-7411; e-mail: domino{at}unc.edu

Spending on antipsychotic medications continues to escalate as new products such as atypicals are increasingly used to treat schizophrenia and other conditions. Given that per person spending on behavioral health benefits is shrinking while spending on pharmaceutical products is increasing, the psychotropic portion of mental health expenditures is likely to continue to increase in the future. The diffusion of these new behavioral health technologies, or the rate at which these products have spread through the market, has been very uneven. Differences in adoption and diffusion rates of psychotropic medications across insurance settings, geographic regions, or subpopulations defined by age, gender, or racial or ethnic groups have important implications for the quality of care received by persons with mental illnesses. This article reviews the evidence on the diffusion of antipsychotic medication and discusses the implications of formulary policies on diffusion, addressing the health care service and administrative context in which the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project is being conducted and which it is intended to inform.

Keywords: Antipsychotic / diffusion / formulary design


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Health Aff (Millwood)Home page
M. Horvitz-Lennon, J. M. Donohue, M. E. Domino, and S.-L. T. Normand
Improving Quality And Diffusing Best Practices: The Case Of Schizophrenia
Health Aff., May 1, 2009; 28(3): 701 - 712.
[Abstract] [Full Text] [PDF]

Home page
 Psychiatr. Serv.Home page
M. E. Domino and M. S. Swartz
Who Are the New Users of Antipsychotic Medications?
Psychiatr Serv, May 1, 2008; 59(5): 507 - 514.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.